Arbitel-40 Use In Pregnancy & Lactation



Micro Labs


Zizawa Healthcare
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: Drugs that act directly on the renin-angiotensin system can cause foetal and neonatal morbidity and death when administered to pregnant women. Oligohydramnios has also been reported, presumably resulting from decreased foetal renal function. When pregnancy is detected, telmisartan should be discontinued as soon as possible.
Telmisartan should not be used by pregnant women.
Telmisartan may cause birth defects or other problems in the baby if taken during pregnancy.
Lactation: It is not known whether telmisartan is excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Telmisartan may pass into breast milk; caution is advised.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in